Rastetter; William H.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Rastetter; William H..The latest application filed is for "therapeutic application of chimeric and radiolabelled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma".

Company Profile

0.15.12

Rastetter; William H. - Rancho Sante Fe CA
Rastetter; William H. - Rancho Santa Fe CA
Rastetter; William H. - San Mateo CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Expression and use of anti-CD20 Antibodies Grant 7,744,877 - Anderson , et al. June 29, 2	2010-06-29
Anti-CD20 antibodies Grant 7,422,739 - Anderson , et al. September 9, 2	2008-09-09
Expression and use of anti-CD20 antibodies Grant 7,381,560 - Anderson , et al. June 3, 2	2008-06-03
Therapeutic Application Of Chimeric And Radiolabelled Antibodies To Human B Lymphocyte Restricted Differentiation Antigen For Treatment Of B Cell Lymphoma App 20080089893 - Anderson; Darrell R. ; et al.	2008-04-17
Induction of cytotoxic T-lymphocyte responses App 20060057162 - Raychaudhuri; Syamal ; et al.	2006-03-16
Therapeutic application of chimeric and radiolabeled antibodies to human B Lymphocyte restricted differentiation antigen for treatment of B cell Lymphoma App 20050186205 - Anderson, Darrell R. ; et al.	2005-08-25
Induction of cytotoxic T-lymphocyte responses App 20040197331 - Raychaudhuri, Syamal ; et al.	2004-10-07
Induction of cytotoxic T-lymphocyte responses Grant 6,733,763 - Raychaudhuri , et al. May 11, 2	2004-05-11
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma Grant 6,682,734 - Anderson , et al. January 27, 2	2004-01-27
New clinical parameters for deteriming hematologic toxicity prior to radioimmunotherapy App 20030211038 - Rastetter, William H. ; et al.	2003-11-13
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma App 20030147885 - Anderson, Darrell R. ; et al.	2003-08-07
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restriced differentiation antigen for treatment of B cell lymphoma App 20030095963 - Anderson, Darrell R. ; et al.	2003-05-22
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma App 20030082172 - Anderson, Darrell R. ; et al.	2003-05-01
Therapeutic application of chimeric and radiolabelled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma App 20030021781 - Anderson, Darrell R. ; et al.	2003-01-30
Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof App 20030012781 - Darrell, Anderson ; et al.	2003-01-16
Therapeutic application of chimeric and radiolabelled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma App 20020197255 - Anderson, Darrell R. ; et al.	2002-12-26
Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphoma Grant 6,399,061 - Anderson , et al. June 4, 2	2002-06-04
Induction of cytotoxic T-lymphocyte responses App 20020039582 - Raychaudhuri, Syamal ; et al.	2002-04-04
Induction of cytotoxic T-lymphocyte responses Grant 6,270,769 - Raychaudhuri , et al. August 7, 2	2001-08-07
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma Grant 5,843,439 - Anderson , et al. December 1, 1	1998-12-01
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma Grant 5,776,456 - Anderson , et al. July 7, 1	1998-07-07
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma Grant 5,736,137 - Anderson , et al. April 7, 1	1998-04-07
Induction of cytotoxic T-lymphocyte responses Grant 5,709,860 - Raychaudhuri , et al. January 20, 1	1998-01-20
Induction of cytotoxic T-lymphocyte responses Grant 5,695,770 - Raychaudhuri , et al. December 9, 1	1997-12-09
Induction of cytotoxic T-lymphocyte responses Grant 5,585,103 - Raychaudhuri , et al. December 17, 1	1996-12-17
Ascorbic acid intermediates and process enzymes Grant 4,758,514 - Light , et al. * July 19, 1	1988-07-19
Ascorbic acid intermediates and process enzymes Grant 4,757,012 - Estell , et al. July 12, 1	1988-07-12

Company Registrations

SEC

0001205903

RASTETTER WILLIAM H

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.